Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice

Journal of Immunology

Volumn 179, Issue 1, 2007, Pages 708-714

  Tabata, Chiharu ^a,b   Tabata, Rie ^c   Kadokawa, Yoshio ^a   Hisamori, Shigeo ^a   Takahashi, Meiko ^a   Mishima, Michiaki ^a   Nakano, Takashi ^b   Kubo, Hajime ^a  

^a KYOTO UNIVERSITY   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c Hyogo Prefectural Tsukaguchi Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BLEOMYCIN; COLLAGEN TYPE 1; COLLAGEN TYPE IALPHA1; CYTOKINE; INTERLEUKIN 6; MESSENGER RNA; RETINOIC ACID; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; IDIOPATHIC DISEASE; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG FUNCTION; LUNG PARENCHYMA; MORTALITY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME;

EID: 34250872717     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.179.1.708     Document Type: Article

References (55)

1. Coultas, D. B., R. E. Zumwalt, W. C. Black, and R. E. Sobonya. 1994. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 150: 967-972.
2. American Thoracic Society/European Respiratory Society. 2002. International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias: this joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 165: 277-304.
3. Gross, T. J., and G. W. Hunninghake. 2001. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 345: 517-525.
4. Mason, R. J., M. I. Schwarz, G. W. Hunninghake, and R. A. Musson. 1999. NHLBI workshop summary: pharmacological therapy for idiopathic pulmonary fibrosis: past, present, and future. Am. J. Respir. Crit. Care Med. 160: 1771-1777.
5. 1, or platelet-derived growth factor B gene. Proc. Natl. Acad. Sci. USA 92: 9570-9574.
6. Tabata, C., H. Kubo, R. Tabata, M. Wada, K. Sakuma, M. Ichikawa, S. Fujita, T. Mio, and M. Mishima. 2006. All-trans retinoic acid modulates radiation-induced proliferation of lung fibroblasts via IL-6/1L-6R system. Am. J. Physiol. 290: 597-606.
7. Tabata, C., Y. Kadokawa, R. Tabata, M. Takahashi, K. Okoshi, Y. Sakai, M. Mishima, and H. Kubo. 2006. All-trans-retinoic acid prevents radiation- or bleomycin-induced pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 174: 1352-1360.
8. Ogata, A., N. Nishimoto, Y. Shima, K. Yoshizaki, and T. Kishimoto. 1994. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood 84: 3040-3046,
9. Sidell, N., T. Taga, T. Hirano, T. Kishimoto, and A. Saxon. 1991. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J. Immunol. 146: 3809-3814.
10. Singhal, S., J. Mehta, R. Desikan, D. Ayers, P. Roberson, P. Eddlemon, N. Munshi, E. Anaissie, C. Wilson, M. Dhodapkar, et al. 1999. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341: 1565-1571.
11. Koch, H. P. 1985. Thalidomide and congeners as anti-inflammatory agents. Prog. Med. Chem. 22: 165-242.
12. Sampaio, E. P., E. N. Sarno, R. Galilly, Z. A. Cohn, and G. Kaplan. 1991. Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes. J. Exp. Med. 173: 699-703.
13. + subset. J. Exp. Med. 187: 1885-1892.
14. Corral, L. G., P. A. Haslett, G. W. Muller, R. Chen, L. M. Wong, C. J. Ocampo, R. T. Patterson, D. I. Stirling, and G. Kaplan. 1999. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J. Immunol. 163: 380-386.
15. D'Amato, R. J., M. S. Loughnan, E. Flynn, and J. Folkman. 1994. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91: 4082-4085.
16. Sheskin, J. 1980. The treatment of lepra reaction in lepromatous leprosy: fifteen years of experience with thalidomide. Int. J. Dermatol. 19: 318-322.
17. Schuler, U., and G. Ehninger. 1995. Thalidomide: rationale for renewed use in immunological disorders. Drug Safety 12: 364-369.
18. Oliver, S. J., S. L. Freeman, L. G. Corral, C. J. Ocampo, and G. Kaplan. 1999. Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis. Clin. Exp. Immunol. 118: 315-321.
19. Lee, F. C., and S. H. Merchant. 2003. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am. J. Hematol. 73: 48-53.
20. Bauditz, J., S. Wedel, and H. Lochs. 2002. Thalidomide reduces tumour necrosis factor a and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50: 196-200.
21. Jacobson, J. M., J. S. Greenspan, J. Spritzler, N. Ketter, J. L. Fahey, J. B. Jackson, L. Fox, M. Chernoff, A. W. L. Wu, L. A. MacPhail, et al. 1997. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection: National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N. Engl. J. Med. 336: 1487-1493.
22. Soler, R. A., M. A. Howard, N. S. Brink, D. Gibb, R. S. Tedder, and D. Nadal. 1996. Regression of AIDS-related Kaposi's sarcomas during therapy with thalidomide. Clin. Infect. Dis. 23: 501-503.
23. Stebbing, J., C. Benson, T. Eisen, L. Pyle, K. Smalley, H. Bridle, I. Mak, F. Sapunar, R. Ahern, and M. E. Gore. 2001. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br. J. Cancer. 85: 953-958.
24. Zeldis, J. B., P. H. Schafer, B. L. Bennett, F. Mercurio, and D. I. Stirling. 2003. Potential new therapeutics for Waldenstrom's macroglobulinemia. Semin. Oncol. 30: 275-281.
25. Zorat, F., V. Shetty, D. Dutt, L. Lisak, F. Nascimben, K. Allampallam, S. Dar, A. York, S. Gezer, P. Venugopal, and A. Raza. 2001. The clinical and biological effects of thalidomide in patients with myelodysplasuc syndromes. Br. J. Haematol. 115: 881-894.
26. Shimoda, M., M. Takahashi, T. Yoshimoto, T. Kono, I. Ikai, and H. Kubo. 2006. A homeobox protein, prox1, is involved in the differentiation, proliferation, and prognosis in hepatocellular carcinoma. Clin. Cancer Res. 12: 6005-6511.
27. Broekelmann, T. J., A. H. Limper, T. V. Colby, and J. A. McDonald. 1991. Transforming growth factor-β is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl. Acad. Sci. USA 88: 6642-6646.
28. Grotendorst, G. R., H. Rahmanie, and M. R. Duncan. 2004. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J. 18: 469-479.
29. Yancopoulos, G. D., S. Davis, N. W. Gale, J. S. Rudge, S. J. Wiegand, and J. Holash. 2000. Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248.
30. Jain, R. K. 2003. Molecular regulation of vessel maturation. Nat. Med. 9: 685-693.
31. Ferrara, N., H. P. Gerber, and J. LeCouter. 2003. The biology of VEGF and its receptors. Nat. Med. 9: 669-676.
32. Thurston, G., J. S. Rudge, E. Ioffe, H. Zhou, L. Ross, S. D. Croll, N. Glazer, J. Holash, D. M. McDonald, and G. D. Yancopoulos. 2000. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 6: 460-463.
33. Fehrenbach, H., M. Kasper, M. Haase, D. Schuh, and M. Muller. 1999. Differential immunolocalization of VEGF in rat and human adult lung, and in experimental rat lung fibrosis: light, fluorescence, and electron microscopy. Anat. Rec. 254: 61-73.
34. Sime, P. J., Z. Xing, F. L. Graham, K. G. Csaky, and J. Gauldie. 1997. Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest. 100: 768-776.
35. Kolb, M., P. J. Margetts, D. C. Anthony, F. Pitossi, and J. Gauldie. 2001. Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis. J. Clin. Invest. 107: 1529-1536.
36. Miyazaki, Y., K. Araki, C. Vesin, I. Garcia, Y. Kapanci, J. A. Whitsett, P. F. Piguet, and P. Vassalli. 1995. Expression of a tumor necrosis factor-α transgene in murine lung causes lymphocytic and fibrosing alveolitis: a mouse model of progressive pulmonary fibrosis. J. Clin. Invest. 96: 250-259.
37. Yaccoby, S., C. L. Johnson, S. C. Mahaffey, M. J. Wezeman, B. Barlogie, and J. Epstein. 2002. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 100: 4162-4168.
38. Desmouliere, A., A. Geinoz, F. Gabbiani, and G. Gabbiani. 1993. Transforming growth factor-β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 122: 103-111.
39. Sime, P. J., Z. Xing, F. L. Graham, K. G. Csaky, and J. Gauldie. 1997. Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest. 100: 768-776.
40. Gomes, I., S. K. Mathur, B. M. Espenshade, Y. Mori, J. Varga, and S. J. Ackerman. 2005. Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: implications in fibrogenesis. J. Allergy Clin. Immunol. 116: 796-804.
41. Elias, J. A., V. Lentz, and P. J. Cummings. 1991. Transforming growth factor-β regulation of IL-6 production by unstimulated and IL-1-stimulated human fibroblasts. J. Immunol. 146: 3437-3443.
42. Zhang, X. L., N. Topley, T. Ito, and A. Phillips. 2005. Interleukin-6 regulation of transforming growth factor (TGF)-β receptor compartmentalization and turnover enhances TGF-β1 signaling. J. Biol. Chem. 280: 12239-12245.
43. Brach, M. A., H. J. Gruss, T. Kaisho, Y. Asano, T. Hirano, and F. Herrmann. 1993. Ionizing radiation induces expression of interleukin 6 by human fibroblasts involving activation of nuclear factor-κB. J. Biol. Chem. 268: 8466-8472.
44. Shibanuma, M., T. Kuroki, and K. Nose. 1994. Inhibition by N-acetyl-L-cysteine of interleukin-6 mRNA induction and activation of NF κB by tumor necrosis factor a in a mouse fibroblastic cell line, BALB/3T3. FEBS Lett. 353: 62-66.
45. Sullivan, D. E., M. Ferris, D. Pociask, and A. R. Brody. 2005. Tumor necrosis factor-α induces transforming growth factor-β1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am. J. Respir. Cell. Mol. Biol. 32: 342-349.
46. Sime, P. J., R. A. Marr, D. Gauldie, Z. Xing, B. R. Hewlett, F. L. Graham, and J. Gauldie. 1998. Transfer of tumor necrosis factor-α to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-β1 and myofibloblasts. Am. J. Pathol. 153: 825-832.
47. Phan, S. H., M. Gharaee-Kermani, B. McGarry, S. Kunkel, and F. W. Wolber. 1992. Regulation of rat pulmonary artery endothelial cell transforming growth factor-b production by IL-β1 and tumor necrosis factor-α. J. Immunol. 149: 103-106.
48. Ye, Q., B. Chen, Z. Tong, S. Nakamura, R. Sarria, U. Costabel, and J. Guzman. 2006. Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease. Eur. Respir. J. 28: 824-831.
49. Moreira, A. L., L. Tsenova-Berkova, J. Wang, P. Laochumroonvorapong, S. Freeman, V. H. Freedman, and G. Kaplan. 1997. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tuber. Lung Dis. 78: 47-55.
50. Lindsay, L., S. J. Oliver, S. L. Freeman, R. Josien, A. Krauss, and G. Kaplan. 2000. Modulation of hyperoxia-induced TNF-α expression in the newborn rat lung by thalidomide and dexamethasone. Inflammation 24: 347-356.
51. Strupp, C., U. Germing, A. Scherer, A. Kundgen, U. Modder, N. Gattermann, and R. Haas. 2004. Thalidomide for the treatment of idiopathic myelofibrosis. Eur. J. Haematol. 72: 52-57.
52. Piccaluga, P. P., G. Visani, S. A. Pileri, S. Ascani, T. Grafone, A. Isidori, M. Malagola, C. Finelli, G. Martinelli, P. Ricci, et al. 2002. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia: a pilot study. Leukemia 16: 1609-1614.
53. Turner-Warwick, M. 1963. Precapillary systemic-pulmonary anastomoses. Thorax 18: 225-237.
54. Peao, M. N., A. P. Aguas, C. M. de Sa, and N. R. Grande. 1994. Neoformation of blood vessels in association with rat lung fibrosis induced by bleomycin. Anal. Rec. 238: 57-67.
55. Chaudhary, N. I., A. Schnapp, and J. E. Park. 2006. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am. J. Respir. Crit. Care Med. 173: 769-776.